PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer files initial beneficial ownership statement
PTCT•Director ownership filing
- PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer reported 46,526 common shares owned, with stock options for 153,875 shares.
